Increasing numbers of infants and children journey by aeroplane, or travel to high altitude destinations, for example, on holiday or as part of a population migration. Most are healthy, although increasingly children may be transported by aeroplane or helicopter specifically to obtain treatment for severe illness or injury. It is therefore useful to review the effects of altitude, and their relevance to children who undertake flights or travel to, or at high altitudes, particularly those with acute and chronic medical conditions.

The published literature on infants and children undergoing airline flights is sparse and limited to case reports and observational studies. There are no studies in the form of trials, for example, to test whether a specific action should be taken or not. This situation exists because firstly, problems in flight are considered rare occurrences; secondly, clinical researchers generally do not deal with large numbers of patients travelling by air; and thirdly, there are substantial logistical problems in undertaking studies involving airline companies and their flights. There is, however, a greater body of data regarding high altitude problems; this is predominantly observational, and has increased our understanding about the more extreme effects of altitude and in particular, hypoxia. Nevertheless, there is little published guidance for the practitioner who is either offering a patient or parent advice, or having to deal with a medical problem in flight. The guidance that does exist is mostly directed towards adults and given against a small evidence base. Hence there is a need to learn more about what happens in flight or at altitude—as such knowledge is accrued, it will be possible to ensure that better guidance on management is provided.

There are a number of environmental changes that arise from altitude, including falls in humidity, irradiation (particularly over the polar areas) temperature, atmospheric pressure, and partial pressure of oxygen. Additional effects that occur as a result of flight include motion, vibration, noise, lack of space, and fatigue, for example, from “jet lag”. Of these physical effects, it is the fall in oxygen levels that is associated with the most potentially serious consequences. Table 1 gives details of the varying oxygen contents in the atmosphere at different altitudes. At sea level, barometric pressure is 760 mmHg (~100 kPa), and air has an atmospheric partial pressure of oxygen (pO₂) of 160 mmHg (~21 kPa)—that is, 21% of barometric pressure.

Airline flights usually cruise at altitudes of 9150–13 000 m (30–40 000 feet) above sea level, where the atmospheric pO₂ is usually ≤5 kPa, which would normally result in a lethal level of airway (alveolar) hypoxia. Aircraft cabins are therefore environmentally modified to atmospheric pressures of 1530–2440 m (5000–8000 feet) above sea level. At the maximum cabin altitude of 2440 m (8000 feet), the atmospheric pressure is 75 kPa (565 mm Hg), giving an atmospheric pO₂ of 15.7 kPa (118 mm Hg). This is equivalent to 15–16% of the ambient oxygen available at sea level.

Serious effects of altitude hypoxia do not usually arise until atmospheric pressure drops to that at about 3000–3500 m (10–12 000 feet), although there is considerable variability in the response to hypoxia between individuals. Air flight regulations require aircraft travel with maximum cabin altitudes of about 2440 m, although a study that measured in-flight cabin altitudes on 204 aircraft flights found the median altitude was 1894 m (6214 feet), with a maximum of 2717 m (8915 feet). It was noted that newer generation aircraft flew at higher altitudes than older aircraft, with a greater risk of altitude exposure to passengers. Thus there may be variable levels of airway hypoxia that occur on commercial airline flights. It is therefore useful to know and recognise the potential risks to infants and children from high altitudes.

**Susceptibility of Infants and Children**

Infants and children have a range of anatomical and physiological differences, which make their responses to illness and stresses, such as altitude exposure, different to adults. These apply particularly to newborns and infants in the first 12 months of life, and are summarised in table 2. Many of the factors listed may contribute to an increased tendency to ventilation-perfusion mismatch in early life, with the result that infants and young children are particularly susceptible to hypoxaemic episodes, particularly with illnesses and airway hypoxia. The adverse effects of chronic hypoxia are well documented, particularly in early infancy and those with chronic lung disease. These include:

- Poor weight gain
- Pulmonary hypertension
- Rise in airway resistance
- Apnoeic-cyanotic episodes
- Life threatening events.

The importance of these factors in the healthy infant, who sustains shorter periods of hypoxia,
The effects of flight and altitude

**Table 1** Atmospheric and partial pressures of oxygen at different altitudes

<table>
<thead>
<tr>
<th>Altitude (m)</th>
<th>Metres</th>
<th>Barometric pressure (kPa)</th>
<th>Atmospheric pO2 (kPa)</th>
<th>Inspired pO2* (kPa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>100</td>
<td>760</td>
<td>21</td>
</tr>
<tr>
<td>1000</td>
<td>3280</td>
<td>90</td>
<td>674</td>
<td>18.9</td>
</tr>
<tr>
<td>2000</td>
<td>6560</td>
<td>80</td>
<td>596</td>
<td>16.8</td>
</tr>
<tr>
<td>3000</td>
<td>9840</td>
<td>70</td>
<td>526</td>
<td>14.7</td>
</tr>
<tr>
<td>5000</td>
<td>16400</td>
<td>54</td>
<td>405</td>
<td>11.3</td>
</tr>
<tr>
<td>8000</td>
<td>26240</td>
<td>36</td>
<td>267</td>
<td>7.6</td>
</tr>
<tr>
<td>10000</td>
<td>52800</td>
<td>26</td>
<td>198</td>
<td>2.5</td>
</tr>
</tbody>
</table>

*Inspired oxygen pressure is calculated from: oxygen fraction in inspired air × (atmospheric pressure − saturation pressure of water at 37°C (6.28 kPa/47.1 mm Hg)).

<table>
<thead>
<tr>
<th>Altitude (m)</th>
<th>Feet</th>
<th>kPa</th>
<th>mm Hg</th>
<th>kPa</th>
<th>mm Hg</th>
<th>kPa</th>
<th>mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>100</td>
<td>760</td>
<td>21</td>
<td>159</td>
<td>20</td>
<td>150</td>
</tr>
<tr>
<td>1000</td>
<td>3280</td>
<td>90</td>
<td>674</td>
<td>18.9</td>
<td>142</td>
<td>17.4</td>
<td>132</td>
</tr>
<tr>
<td>2000</td>
<td>6560</td>
<td>80</td>
<td>596</td>
<td>16.8</td>
<td>125</td>
<td>15.4</td>
<td>115</td>
</tr>
<tr>
<td>3000</td>
<td>9840</td>
<td>70</td>
<td>526</td>
<td>14.7</td>
<td>111</td>
<td>13.4</td>
<td>100</td>
</tr>
<tr>
<td>5000</td>
<td>16400</td>
<td>54</td>
<td>405</td>
<td>11.3</td>
<td>85</td>
<td>10.0</td>
<td>75</td>
</tr>
<tr>
<td>8000</td>
<td>26240</td>
<td>36</td>
<td>267</td>
<td>7.6</td>
<td>56</td>
<td>6.2</td>
<td>46</td>
</tr>
<tr>
<td>10000</td>
<td>52800</td>
<td>26</td>
<td>198</td>
<td>2.5</td>
<td>42</td>
<td>4.2</td>
<td>32</td>
</tr>
</tbody>
</table>

*For example, arising from falls in inspired pO2, respiratory infections, or chronic lung disease.

Table 2 Factors increasing the susceptibility of infants and young children to hypoxaemia

- Predisposition for paradoxical inhibition of respiratory drive (up to 1–2 months of age)
- In early infancy, infections/hypoxia may present with apnoea/hypoxia
- More compliant rib cage
- Negative intra-thoracic (pleural) pressures less effective (i.e. less suck is generated)
- Provides less support of lung volume, particularly during active sleep
- Reduced surfactant (preterm newborns)
- Increases tendency to atelectasis and hypoxia
- Preterm infants would not usually travel, except as part of a medical transfer
- Increased proportion of the pulmonary vascular bed with muscular arterioles (early infancy)
- Pulmonary vascular responses to inspired hypoxia are greater in older infants than in newborns, and in those with perinatal vascular insults
- Rise in pulmonary vascular resistance contributes to right to left shunting, ductal opening (in the early neonatal period), further ventilation-perfusion mismatch, and hypoxia
- Increased airway reactivity in response to hypoxia (infancy)
- Airway or alveolar hypoxia* causes pulmonary vasoconstriction
- Infants at 26 weeks of age show greater desaturation on histamine challenge than infants 4 weeks old
- Lung volume at end expiration similar to closing volume (early infancy)
- Small airway closure, and hence non-ventilated units, occur more readily, e.g. during active sleep, feeding, and crying
- Reduced upper and lower internal diameters of the airways
- Airway conductance falls from birth to 2 months of age
- Reductions in diameter from e.g. respiratory infection, reduces airway patency sooner, increasing tendency to airway closure and ventilation-perfusion mismatch
- Fewer alveoli (early childhood)
- Growth in the alveolar region greater than that in the airways in early infancy
- Increases the susceptibility to mismatch between ventilation and perfusion
- Fetal haemoglobin present up until 4–6 months of age
- Oxygen dissociation curve is shifted to the left, so oxygen is given up less readily to the tissues
- At any given pO2, the SaO2 is higher, consistent with the higher values reported at 3100 m in neonates compared to values at 4 months of age.

\* For example, arising from falls in inspired pO2, respiratory infections, or chronic lung disease.
Tibet suggest that there are also genetically inherited factors that lend protection against hypoxaemia at high altitudes. Hypoxaemia has been identified at altitude as a more useful predictor of illness severity, and was strongly associated with mortality in acute illness. Recognition has therefore been given to the value of pulse oximetry and a need for further exploration of its role in this clinical setting. More understanding of the effects of altitude related hypoxia has come from experimental studies than from those in children living at high altitude.

EFFECTS OF HYPOXIA

Exposure to hypoxia is usually followed by increased minute ventilation, mainly as a result of increased tidal volume. Newborn infants, born at either full term or preterm, show a characteristic biphasic response, with a transient increase in ventilation followed by a decline by 3–5 minutes. This decrease in ventilation may persist for some time after the reinstatement of normoxic breathing. This biphasic response is short lived, usually disappearing after a few weeks of age, but may persist longer in infants born preterm. This may make them prone to greater degrees of hypoxaemia in relation to ambient hypoxia. The respiratory depressant effect appears to be related to a prolongation in expiratory time; this was found not to be due to alteration of the Hering-Breuer reflex, which involves vagal activity.

In 34 healthy infants, exposure to 15% oxygen for six hours at sea level produced hypoxaemia, with a median fall in SaO2 of 1%. The response was highly variable (range 9.3% to 0.7%), and not predicted from baseline variables of oxygenation, respiratory rate, or pattern. There was a decrease in regular breathing pattern (equated to quiet sleep), more time spent in periodic breathing, and interestingly a decrease in prolonged apnoeic pauses. The latter is opposite to the effect noted in preterm newborns, where increased apnoea occurred.43 Episodic desaturation occurred much more frequently, and baseline levels below 80% stopped the exposure in four infants after 1.9–5.2 hours. None of the infants aroused to the hypoxaemia.

Another sea level study subjected thirty 5–7 year olds to 12% oxygen for 10 minutes; 7 of 10 whose SaO2 fell ≤88% had histories of reactive airway disease. Desaturation was a greater predictor for reactive airway disease than spirometry (positive predictive values 70% and 30% respectively); desaturation had a sensitivity of 100% for reactive airway disease. This suggests that small airway disease contributes to the susceptibility to desaturate with exposure to hypoxia. This may be because airway/alveolar hypoxia induces bronchoconstriction.

It is not possible to predict on first exposure to hypoxia the degree of hypoxaemia and any systemic effect, without

| Table 3 | The physiological effects of high altitude
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory</td>
<td>Acute effect</td>
</tr>
<tr>
<td>Arterial pO₂ and oxygen saturation</td>
<td>↓</td>
</tr>
<tr>
<td>Minute ventilation</td>
<td>↑</td>
</tr>
<tr>
<td>Carbon dioxide</td>
<td>↓</td>
</tr>
<tr>
<td>Oxygen consumption/CO₂</td>
<td>↓</td>
</tr>
<tr>
<td>Lung volumes (vital capacity, residual volume)</td>
<td>↑</td>
</tr>
<tr>
<td>Lung compliance</td>
<td>↑</td>
</tr>
<tr>
<td>Peak flow/forced expiratory volume</td>
<td>↓</td>
</tr>
<tr>
<td>in 1 s</td>
<td>↑</td>
</tr>
<tr>
<td>Lung gas transfer (DLCO)</td>
<td>↓</td>
</tr>
<tr>
<td>Nocturnal arousals/less active sleep</td>
<td>↑</td>
</tr>
<tr>
<td>Periodic breathing</td>
<td>↑</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Heart rate</td>
</tr>
<tr>
<td></td>
<td>Cardiac output</td>
</tr>
<tr>
<td></td>
<td>Pulmonary artery pressure</td>
</tr>
<tr>
<td></td>
<td>Pulmonary vascular resistance</td>
</tr>
<tr>
<td></td>
<td>Capillary leak</td>
</tr>
<tr>
<td></td>
<td>Erythropoietin and red blood cell production</td>
</tr>
<tr>
<td>Neurological</td>
<td>Cerebral blood flow</td>
</tr>
<tr>
<td></td>
<td>Intracranial pressure</td>
</tr>
<tr>
<td>Body growth</td>
<td>Birth weight</td>
</tr>
<tr>
<td></td>
<td>Postnatal growth</td>
</tr>
</tbody>
</table>

Comparisons are related to sea level values: → no difference; ↑ increased; ↓ reduced.
Data relates to children where it exists (see text)
*May be accounted for by factors such as socioeconomic deprivation.

| Table 4 | Normal SaO₂ levels at different altitudes
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Altitude (m)</td>
<td>Location</td>
<td>n studied</td>
<td>Age</td>
<td>SaO₂ (%)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Sea level</td>
<td>UK</td>
<td>70</td>
<td>2–16 y, mean 8 y</td>
<td>Range 95.8–100 31</td>
</tr>
<tr>
<td></td>
<td>Peru</td>
<td>189</td>
<td>2 mth–5 y</td>
<td>Range 96–100 32</td>
</tr>
<tr>
<td>1610</td>
<td>Colorado</td>
<td>150</td>
<td>&lt;48 h</td>
<td>Mean 98.7 ± 1.1 33</td>
</tr>
<tr>
<td></td>
<td>Mean 93.0 ± 0.2</td>
<td>1670</td>
<td>Nairobi</td>
<td>87</td>
</tr>
<tr>
<td>2640</td>
<td>Bogota</td>
<td>189</td>
<td>5 days–24 mth</td>
<td>Range 89.3–99.3 35</td>
</tr>
<tr>
<td>2800</td>
<td>Colorado</td>
<td>72</td>
<td>3–670 days</td>
<td>Mean 93.3 ± 2.1</td>
</tr>
<tr>
<td>3100</td>
<td>Colorado</td>
<td>14</td>
<td>6 h–4 mth</td>
<td>Mean 89–97</td>
</tr>
<tr>
<td></td>
<td>Mean 91.7 ± 0.2</td>
<td>3658</td>
<td>Tibet</td>
<td>15</td>
</tr>
<tr>
<td>4540</td>
<td>Peru</td>
<td>153</td>
<td>0.5–72 h</td>
<td>Mean 88.9 ± 2.9</td>
</tr>
</tbody>
</table>

Values given are those in (quiet) sleep.
*Ranges for babies gestated and born to immigrant Chinese mothers, and babies whose families have lived at this altitude for innumerable generations.

www.archdischild.com
undertaking some pre-exposure challenge test (see later in “Use of oxygen therapy”). Subsequently, individuals may have a repeatable response to hypoxia. Although this knowledge is important for patients with already identified medical conditions, it is those who are healthy and travelling to high altitude destinations who would most benefit from knowledge of their individual response, in order to reduce the risk of serious or life threatening conditions, such as high altitude pulmonary or cerebral oedema.

**HIGH ALTITUDE PROBLEMS**

Acute mountain sickness, high altitude pulmonary oedema, and high altitude cerebral oedema usually occur over 2400 m (8000 feet) above sea level and represent the extreme effects of altitude related hypoxia. **Acute mountain sickness** is the mildest manifestation of altitude illness and is more readily reversible than pulmonary or cerebral oedema. Rapid ascent and previous episodes of acute mountain sickness are important risk factors. By symptom recognition, 28% of 558 children travelling from 1600 m to 2835 m developed acute mountain sickness. However, 21% of 405 children developed similar symptoms on travel to sea level, suggesting the true incidence of this complication is 7%, and that travel itself imposes a significant stress on a child. Pre-verbal children are unable to cooperate with the self reporting needed to diagnose acute mountain sickness. To overcome this, there have been attempts to score such children with a “fussiness” score, and this estimated 21% of children 3–36 months old as suffering acute mountain sickness on travel from 1610 m to 3488 m. This compared well with an incidence of 20% in 45 adults, using a conventional scoring system.

Acute mountain sickness presents with headache, nausea, vomiting, anorexia, weakness, and insomnia. There may be peripheral oedema, and in a few cases inspiratory crackles on examination. Symptoms start 12–24 hours after arrival at altitude, and worsen over 2–3 days before resolving. Resolution usually occurs with rest and no further ascent. **Dexamethasone** helps relieve symptoms (in addition to simple analgesia), alone or in combination with acetazolamide. Although not formally evaluated in children, acetazolamide has also been used to prevent acute mountain sickness.

**High altitude pulmonary oedema** is more serious, but fortunately less common. In Leadville, Colorado (3100 m), high altitude pulmonary oedema occurred in 50/100 000 of the population, but for 140/100 000 when limiting the analysis to 1–14 year olds. Most episodes began 1–3 days after return from a 2-7 day visit to a low altitude, but “lowlanders” visiting at high altitude were also affected. Rapid ascent, exertion, cold exposure, and previous episodes of high altitude pulmonary oedema are risk factors. Symptoms include shortness of breath, cough, and chest pain, and are accompanied by increased heart and respiratory rates, cyanosis, crackles, mild fever, and a loud second heart sound. Chest x ray examination shows bilateral pulmonary infiltrates, and with mild leukocytosis and fever can give a presentation initially indistinguishable from pneumonia. The oedema may progress to produce respiratory failure, coma, and death. Treatment includes oxygen therapy, rest, and in the more severe case, descent to lower altitude. Other effective therapies include nifedipine (0.5 mg/kg/dose 8 hourly), positive airway pressure, and phentolamine.

**High altitude cerebral oedema** is a rarer and more severe manifestation of acute mountain sickness, which has the same clinical features, but in addition visual disturbance, dizziness, impaired memory, hallucinations, ataxia, disorientation, and retinal changes (for example, haemorrhages and papilloedema). Such cases can rapidly progress to coma and death. Treatment includes oxygen, descent, and dexamethasone (0.15 mg/kg/dose 4 hourly).

**Chronic mountain illness** refers to the situation where many of the above features develop more slowly. It is seen predominantly in the older population who have lived in high altitude regions of the world, rather than children, and responds to descent to a lower altitude. However, there is evidence that newborns may develop chronic hypoxia related problems. Of 15 Han (Chinese) infants gestated and born in Tibet at 3658 m above sea level, 14 repeatedly had cyanotic episodes during sleep, with feeding, and with minor respiratory illnesses, compared to only 1/15 infants born to indigenous Tibetan mothers. The Han infants had lower SaO2 levels, and three developed evidence of a circulatory disorder (murmur and gallop, central cyanosis, pedal oedema). It is probable that these infants had early or developing stages of **subacute infantile mountain sickness**, which can cause death from pulmonary hypertension and right heart failure.

Awareness of the manifestations of altitude related illness and the factors that make infants and young children susceptible helps in making recommendations about altitude exposure.

**SUSCEPTIBILITY TO ALTITUDE PROBLEMS**

Two important factors contributing to acute mountain sickness includes a poor hypoxic ventilatory response and a loss of the normal diuresis seen at altitude. The hypoxic ventilatory response is the increase in minute ventilation mediated by hypoxia on the carotid body, leading to stimulation of the brain stem respiratory centre. If this does not occur, then there is not the increased exhalation of carbon dioxide, the development of a respiratory alkalosis, and a resultant (protective) cerebral vasoconstriction. This, in conjunction with increased blood volume, probably contributes to increased cerebral blood flow and the development of mild cerebral oedema in the form of acute mountain sickness.

High altitude pulmonary oedema is linked to an individual’s tendency to respond to hypoxia with an abnormally increased pulmonary artery pressure. As the pulmonary hypertension arises from vasoconstriction of pre-capillary arterioles, it is unclear how raised pulmonary artery pressures lead to pulmonary oedema. It may occur as a result of capillary leak from increased hydrostatic pressures, in areas not protected by the hypoxia induced vasoconstriction. Alternatively, the integrity of the alveolar capillary membrane may be damaged itself by hypoxia, or from inflammatory mediators.

That inflammatory mediators might be involved in altering the integrity of the capillary-alveolar membrane is supported by the finding that 79% of children in whom high altitude pulmonary oedema developed had a respiratory infection in the two weeks before arrival at altitude, compared to only 13% of adults (child controls were not used). As a marker of inflammatory response, eight patients with asthma and a mean age of 14 years who returned to an altitude of 1560 m after a 14 day break at sea level, showed increases in airway reactivity and inflammatory mediators, compared to controls who stayed at altitude.

More recently, it has been shown that genetic factors may play an important role in protection against the effects of altitude. The presence of a specific angiotensin converting enzyme (ACE) genotype (I allele), resulting in low ACE activity, is associated with protection of SaO2 levels in climbers who ascend rapidly to over 5000 m. In addition, climbers susceptible to high altitude pulmonary oedema were more likely to have certain genetic markers associated with low levels of nitric oxide production in the lung.
These data are useful in helping understand the reasons for some individuals’ susceptibility to the effects of altitude related hypoxia.

HYPOXIA AND THE SUDDEN INFANT DEATH SYNDROME

There is dispute as to whether the effects of high altitude hypoxia are related to sudden and unexpected infant death. However, there is epidemiological, pathological, and clinical evidence that links hypoxia to sudden death. That severe hypoxaemic episodes can lead to sudden death supports such an association. There is also a high prevalence of hypoxaemia in preterm infants who have suffered near death events. In addition, epidemiological studies have identified that the groups of infants who are at risk of subclinical hypoxaemia—preterm infants, those with respiratory infections, and those who have suffered apparent life threatening events—are also groups with an increased risk of sudden infant death. Other epidemiological studies have shown a link between mortality and altitude.

Getts and Hill examined the number of infants dying of sudden infant death syndrome (SIDS) and birth rates in the state of Nebraska for the period 1973 to 1978, and categorised the counties into 13 different bands of altitude. There was a strong correlation between altitude and SIDS rates, which did not apply to other post-neonatal deaths. At 300 m, SIDS accounted for 25% of all post-neonatal deaths, and increased as a proportion with altitude, until at 1500 m, SIDS accounted for 55% of deaths. SIDS infants died at a mean of 9 weeks of age at 1200 m, compared to 17 weeks of age at 300 m, suggesting that hypoxia from higher altitudes might accelerate any susceptibility to sudden death. Although social class was not controlled for, SIDS infants at altitude had higher levels of prenatal care.

In Colorado, the mortality rate in preterm infants at altitude (≥2740 m) was 73% higher than at <2130 m. This difference was attributable to respiratory deaths, and did not exist for non-respiratory deaths. Because birth weights were lower at higher altitudes (and this applied at all gestations), it was postulated that intra-uterine hypoxia might affect fetal lung development and increase the risk for preterm mortality. This could include a greater tendency to suffer hypoxaemia, which has been linked to increased respiratory mortality. A subsequent review of deaths in Colorado found no effect of altitude on the absolute numbers of SIDS or non-SIDS deaths; however, this was not related to population mortality rates.

In Austria, the risk of SIDS increased gradually at higher altitudes in a dose-response fashion (odds ratio 1.12/100 m; 95% confidence intervals 1.02 to 1.24). This relation was even stronger for infants lying prone, a known risk factor for SIDS (odds ratio for >1000 m compared to ≤600 m, 4.4). In this study, socioeconomic variables were controlled for. The authors concluded that the higher rate of SIDS with increasing altitude may be accounted for by the relative environmental hypoxia for the infant, the effects of maternal hypoxia on fetal growth, or colder outdoor temperatures, with resultant increased thermal environment indoors (also postulated as a potential risk mechanism for SIDS).

It has previously been discussed that an abnormal hypoxic ventilatory response increases the risk for high altitude illness. Similarly, infants who have suffered apparent life threatening events, often considered a living model for SIDS, have been described as having smaller increases in tidal volume, and poorer arousal responses in response to hypoxia or hypercapnia, compared to controls.

There is pathological support for the association between hypoxia and SIDS: Naeye found pathological markers for hypoxia in infants who died of SIDS, and increased muscle in the pulmonary arterioles has been reported in SIDS infants. Nevertheless, despite the above evidence linking altitude related hypoxia and sudden death, the altitude in aircraft cabins is probably not sufficiently high to cause major problems. In the UK’s Confidential Enquiry into Stillbirths and Deaths in Infancy (CESDI, 1995–96), questions on the use of air travel were made to parents of 130 cases of sudden infant death syndrome (SIDS) and 528 controls. None of the infants who died had flown, compared with two controls. However, the sample size may have been too small to discount a relation between air travel and sudden infant death.

Despite case reports, the evidence that suggests there is an increased chance of infants dying during and in the first few days after a long haul airline flight is not strong enough to make recommendations that infants should not fly. Milner concluded in an associated editorial that flying appears to be safe for healthy children in the first year of life. It has also been suggested that care is taken in the use of sedatives and undertaking flights with current respiratory infections, particularly in infants under 1 year of age. Further study is warranted to examine these risks.

USE OF OXYGEN THERAPY

In the normative studies undertaken in children at altitude, a key question for researchers was when oxygen therapy should be administered. For example, should a healthy child who has SaO2 levels below the normal range at any given altitude receive additional inspired oxygen? Clinicians have given additional oxygen to infants without pulmonary disease to maintain SaO2 >90% at 1610 m, and >88% at 2800 m. It has already been described that infants at high altitude have lower levels of SaO2 compared to sea level (see table 4), and a proportion at higher altitudes will develop pulmonary hypertension, right heart failure, and death. In the presence of respiratory problems, it would seem prudent to use oxygen therapy to maintain levels of SaO2 in the higher end of the relevant normal range.

In Austria, cardiac catheterisation in infants with bronchopulmonary dysplasia, has shown that pulmonary hypertension develops when SaO2 falls from 96–98% to 93–94%, with the greatest changes occurring when SaO2 was below 90%.

In an attempt to determine whether patients with underlying medical problems should receive additional inspired oxygen when flying by aeroplane, methods have been devised to challenge the patient with a hypoxic environment similar to that in the flight cabin. The hypoxia altitude simulation test (HAST) involved 22 adult patients with chronic obstructive lung disease who were given 20.9%, 17.1%, 15.1%, and 13.9% inspired oxygen to determine the effects of hypoxia at 1524 m, 2438 m, and 3048 m (5000, 8000 and 10 000 feet) above sea level. This study involved extensive monitoring, including the use of arterial blood samples. The sea level arterial pO2 was found to be the best predictor of altitude arterial pO2, poor predictors were lung function studies, respiratory acidosis, and exercise tolerance.

In another study, 30 adults were put into a body plethysmograph with 15% oxygen, SaO2 levels were monitored and then the flow of additional inspired oxygen determined to restore SaO2 levels to 90% or baseline levels in 21% oxygen. When patients were given 2 litres/minute oxygen by nasal cannulae while still in 15% ambient oxygen, SaO2 levels were restored in all but one patient, who needed 3 litres/minute. The authors concluded that provided SaO2 levels were not raised above the patients’ usual level, no significant change in arterial carbon dioxide levels should occur.
A study in 22 children aged 11–16 years with cystic fibrosis measured responses to 15% oxygen before a flight to a high altitude destination (1800 m). The laboratory test was 100% sensitive and highly specific in identifying those at risk of showing desaturation below 90%. Even though in adults, there is some reproducibility in individual response to exposure to high altitude, individual tolerance to hypoxia is extremely variable. The authors therefore concluded that the test could identify only a group among whom clinical problems are more likely to arise. Patients with cystic fibrosis have previously been identified as being at risk of high altitude. More recently, patients with other chronic lung conditions have been assessed by placing the patient in a body box filled with 15% O2 and then titrating the flow needed to raise SaO2 levels to normal. For infants, this can be done by placing them on the parent’s lap (Buchdahl R and Bush A, personal communication).

None of these tests subjected patients to exposures of oxygen for durations that may occur on transcontinental flights. Parkin et al found that desaturation to <80% for ≥1 minute occurred on exposure to 15% oxygen in 4/34 healthy infants, but after variable periods of time: 1.9–5.2 hours (median exposure time to 15% oxygen was 6.3 hours). Only more prolonged studies undertaken in infants exposed to hypoxic environments, such as during long haul flights or at high altitude destinations, will answer the question as to whether duration of exposure affects the degree of response.

AIR TRANSPORT OF SICK CHILDREN

Transport of sick neonates and children to specialised units can occur by aeroplane or helicopter to allow large distances to be covered quickly. In this setting, it is important to consider other effects of the transport, as well as those of hypoxia. These include expansion of trapped gases, stress from noise, vibration, and motion, and decreased temperature. If the patient is receiving additional inspired oxygen, the fractional inspired oxygen concentration may be increased to account for the hypoxia at altitude. This is best titrated during the journey by continuous pulse oximetry, as was done, for example, in the 4907 mile transfer from Vancouver, Canada to London, England of a 6 year old boy for heart-lung transplantation. In this case, the aircraft (Lear 35) travelled at low altitude (maximum cabin pressure of 3700 feet) to ensure SaO2 levels of at least 80%. In patients who are ventilated, it would also be possible to increase the positive end expiratory pressure to help oxygenation. Positive gravity (G) forces during take off and landing can result in pooling of blood, for example, in the lower extremities on take off if the head is placed towards the front of the aircraft. Such effects may be harmful in shock, as can the pooling of blood to the head in cases of raised intracranial pressure. Positive airway pressure respiratory support may enhance the effects of gravity forces, while patient placement perpendicular to the direction of travel reduces these effects.

Gases expand at altitude (100 ml at sea level becomes 130 ml at 1830 m (6000 feet) and 400 ml at 10 000 m). This may have adverse effects on gases trapped in body cavities such as the pleural space, gut, and middle ear. Without anticipation and management of these problems, severe discomfort, pain, and clinical instability may occur. These may result from pneumothorax, pneumomediastinum, pulmonary interstitial emphysema, and subcutaneous emphysema. Abnormal air collections, such as might occur in the pleural space, should be drained before transport by air. Intrapulmonary cysts invariably seem to equilibrate on ascent and do not rupture. Pressurised cabins will reduce the likelihood of gas expansion problems.

Helicopters produce more stress from vibration and noise than do fixed wing aircraft, which is mostly not preventable. However, the stress from these may particularly disturb the sick neonate, producing hypoxaemia, apnoea, or bradycardia. Temperature regulation should be maintained, as hypothermia and shivering increase oxygen consumption, and may aggravate metabolic acidosis and hypoglycaemia in sick patients. As the humidity drops with altitude, additional means should be used to provide this, for example, in inspired gases. This will help temperature control, fluid balance, and the tenacity of secretions.

OTHER MEDICAL CONDITIONS

There is little published advice on the suitability of flying or travel to high altitude for medical conditions other than those where hypoxia is a risk factor. For example, advice on the timing of travel after surgery, particularly when air has entered a body cavity, is predominantly down to the views of individual practitioners. British Thoracic Society Guidelines recommend waiting two weeks after uncomplicated thoracic surgery, and six weeks after resolution of a pneumothorax. Surprisingly, these guidelines do not mention avoidance of flying during acute asthma exacerbations.

There has been discussion of the risks of flying with serous otitis media (glue ear): the danger is of either air in the middle ear not escaping as expansion occurs on ascent, or of air not entering the middle ear on descent, because of Eustachian tube dysfunction. This failure to equilibrate pressures in the middle ear is more likely in children with adenoidal hypertrophy, and recurrent otitis media. Middle ears that are filled entirely with fluid are probably less likely to cause problems, than those where there is a fluid-air interface. Because air travels more easily from the ear to nasopharynx, descent is potentially more of a problem. If the Eustachian tube does not vent, the tube may block because of the higher atmospheric pressures. Simple manoeuvres, such as swallowing, drinking liquids, and Valsalvas during ascent and descent may help avoid such problems. Alternatively, nasal decongestants have been used 1–2 hours before take off, and 30 minutes before descent.

Patients with sickle cell disease are at risk from sickling crises during flight. This particularly applies to patients with splenomegaly and relatively higher blood viscosity (for example, from near normal haemoglobin levels). Thus patients with HbSC and sickle cell thalassaemia are more at risk, such that oxygen therapy has been recommended at altitudes over 2135 m (7000 feet). These recommendations suggested that for classical sickle cell disease, where the spleen was known to have previously auto-infarcted, travel in pressurised aircraft should not pose a problem.

ADVICE FOR TRIPS TO HIGH ALTITUDE

With increasing numbers of families and children travelling to high altitude locations for holidays, information needs to be provided about the risks of high altitude illness so that informed decisions can be made. Factors previously discussed that lead to an increased risk of acute illness include:

- Young age
- Exercise
- Genetic susceptibility
- Recent infection
- Rapid ascent
- High altitude
- State of hydration
- Underlying illness.
The importance of gradual ascent is stressed, but is not always possible with increasing accessibility of high altitude locations. Rest on arrival, maintenance of good hydration, and the early recognition of new symptoms as being possibly due to high altitude illness are recommended. In pre-term or ill infants, and in children with some non-specific symptoms such as irritability, clinginess, excessive crying, poor appetite, lethargy, and vomiting should be assessed with altitude related problems borne in mind.

Recent recommendations for children included advice to start descent immediately in any child who becomes unwell above 2500 m. Because of the risks of subacute infantile mountain sickness, it was also recommended that children under 2 should sleep no higher than 2000 m, and children 2-10 years, no higher than 3000 m. In addition, travellers should be aware of the underlying illnesses that increase susceptibility to hypoxia related problems, shown in Table 5.

**MANAGEMENT OF COMMON MEDICAL EMERGENCIES**

Medical emergencies in infants and children in flight are fortunately uncommon. If a child has a known medical condition, then it is important that the parents/careers are clear about how to deal with potential problems. These are usually no different from those that may occur everyday, although the stress of long distance travel, and the changes in physical environment in an aircraft cabin and of time zone, increase the likelihood of a deterioration in most physical conditions. Consultation with the physician who usually manages the child's medical condition is advised prior to long flights, particularly where the stability of the child's condition is less than optimal, or where clinical deterioration has potentially serious or life threatening consequences.

Although the passenger lists on many flights include one or more health professionals who might provide emergency care, it would be foolish for all parents/careers to be trained in basic life support. Basic information on how to treat medical emergencies in infants and young children is well covered in a number of standard texts, such as *Advanced paediatric life support*. However, the presence and standard of drug kits and medical equipment varies enormously between different airlines, making precise guidance on management in an aircraft difficult.

**REFERENCES**


**Table 5. Medical conditions with increased risk for hypoxia related problems**

<table>
<thead>
<tr>
<th>Chronic lung disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Of prematurity</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
</tr>
<tr>
<td>Sleep related upper airway obstruction</td>
</tr>
<tr>
<td>Reactive airway disease</td>
</tr>
<tr>
<td>Chest wall conditions</td>
</tr>
<tr>
<td>Muscle weakness, e.g. muscular dystrophy</td>
</tr>
<tr>
<td>Restrictive lung disease, and other rib cage disorders</td>
</tr>
<tr>
<td>Infections</td>
</tr>
<tr>
<td>Respiratory: upper and lower</td>
</tr>
<tr>
<td>Haematological</td>
</tr>
<tr>
<td>Sickle cell diseases, e.g. SC, trait</td>
</tr>
<tr>
<td>Cardiac conditions</td>
</tr>
<tr>
<td>Increased pulmonary blood flow, e.g. venricular septal defect, patent arterial duct</td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
</tr>
<tr>
<td>Heart failure</td>
</tr>
<tr>
<td>Cardiomyopathy</td>
</tr>
<tr>
<td>Arrhythmias</td>
</tr>
<tr>
<td>Neurological</td>
</tr>
<tr>
<td>Seizure disorder with respiratory effects</td>
</tr>
<tr>
<td>Brain stem disorder (with bulbbar effects or sleep disordered breathing)</td>
</tr>
<tr>
<td>Raised intracranial pressure</td>
</tr>
</tbody>
</table>
The effects of flight and altitude


